The study evaluates the efficacy of a new quadrivalent mRNA influenza vaccine, finding it to be highly immunogenic and protective in a mouse model. Compared to traditional vaccines, the mRNA-based option offers advantages like reduced production time and elimination of the risk of growth-promoting mutations.
H1 2023 RESULTS – Major advances in clinical programs – Extension of cash horizon to February 2024 – Biotech Investments
EQS-News: Affluent Medical SA / Key word(s): Half Year Results Affluent Medical SA: H1 2023 RESULTS – Major advances in clinical programs – Extension of